ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Psychopharmacology of Fear-Potentiated Startle in Humans

This study is currently recruiting participants.
Verified by National Institutes of Health Clinical Center (CC), June 2008

Sponsored by: National Institute of Mental Health (NIMH)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00044096
  Purpose

The purpose of this study is to understand the effects of the drug alprazolam (Xanax ) on anxiety.

To understand the effect of anxiety-relieving drugs on fear and anxiety, researchers often have participants anticipate unpleasant stimuli. Anticipating unpleasant stimuli increases or potentiates a simple reflex called the startle reflex. The so-called fear-potentiated startle reflex (FPS) effect may be blocked or reduced by anxiety-relieving drugs. Evidence suggests that the FPS can be mediated by two mechanisms that regulate the phasic- and sustained enhancement of startle. This study will elicit phasic and sustained FPS in participants by having them anticipate moderately painful stimuli that are administered predictably and unpredictably. The main goal of this study is to assess the affect of alprazolam on the phasic and sustained enhancement of startle.

This study comprises two pilot experiments and a main study. Participants in the study will be screened with a psychiatric history, physical examination, electrocardiogram (EKG), and blood and urine tests. Participants will four testing sessions separated by 5 to 10 days. At each session, participants will be given one of two doses of alprazolam, diphenhydramine, or placebo (an inactive pill). Questionnaires and other tests will be performed.


Condition
Healthy

MedlinePlus related topics:   Anxiety   

Drug Information available for:   Escitalopram    Benzetimide    Citalopram    Citalopram hydrobromide    Dexetimide    Escitalopram oxalate    Diphenhydramine    Diphenhydramine citrate    Diphenhydramine hydrochloride    Promethazine    Promethazine hydrochloride   

U.S. FDA Resources

Study Type:   Observational
Official Title:   Psychopharmacology of Fear-Potentiated Startle in Humans

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment:   166
Study Start Date:   August 2002

Detailed Description:

A lack of adequate experimental models of emotional reactions to aversive stimuli is an impediment to furthering our understanding of the psychopharmacology of fear and anxiety in humans. Finding procedures that enable us to test putative anxiety-relieving agents would greatly facilitate this type of research. The startle reflex is an ideal tool for such an endeavor. The so-called fear-potentiated startle reflex (FPS) has clear face validity, well-defined neuronal system, and cross-species generalization. In addition, in rodents the fear-potentiated startle reflex effect is blocked or reduced by drugs that are anxiolytic in humans. However, the few psychopharmacological studies conducted so far in humans have yielded inconsistent results. One possibility is that prior studies have not employed optimal designs to test the effects of anxiolytics. Our previous studies in anxious individuals and patients with anxiety disorders, as well as animal studies, suggest that the potentiation of startle by aversive states can be mediated by two distinct psychological and neurobiological mechanisms. One mediates the short-term potentiation of startle to explicit threatening cues, and the other the long-term potentiation of startle by contextual cues. We have shown that the benzodiazepines alprazolam act preferentially on FPS to contextual cues. The objectives of the following studies are to further test the psychopharmacological validity of the model using recognized anxiolytics (the SSRI citalopram), to test the anxiolytic properties of compounds that are hypothesized to be anxiolytic (the angiotensin receptor blocker candesartan) based on pre-clinical data, and to examine the role of cortisol in startle potentiation.

  Eligibility
Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Criteria
  • INCLUSION CRITERIA:

Subjects will be healthy volunteers between 18-45 years old and free of current psychopathology and organic central nervous system disorders.

EXCLUSION CRITERIA:

  • Any significant medical or neurological problems (e.g. cardiovascular illness, respiratory illness, neurologic illness, seizure, etc.)
  • Adverse reactions to ACE inhibitors and ACE receptor antagonists (candesartan study only)
  • Adverse reactions to cortisol (cortisol study only)
  • History of angioedema
  • Osteoporosis (Hydrocortisone study only)
  • Blood pressure below 100 (candesartan study only)
  • Use of potassium supplements (candesartan study only)
  • A family history of mania, schizophrenia, or other psychoses
  • A history of mania, schizophrenia, or other psychoses
  • Current migraine
  • Use of herbal medicines or dietary supplements with psychoactive properties (citalopram study only)
  • Any current psychiatric disorders
  • Past alcohol/drug dependence and alcohol/drug abuse in past one year
  • Current use of psychotropic medication
  • Use of diuretics or laxatives (candesartan study only)
  • Impaired hearing
  • Reduced startle reactivity
  • Pregnancy
  • Positive results of beta-human chorionic gonadotropin testing (females only)
  • Neurological syndrome of the wrist (e.g., carpal tunnel syndrome)
  • Adverse reaction to candesartan or other blood pressure lowering medications
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00044096

Contacts
Contact: Patient Recruitment and Public Liaison Office     (800) 411-1222     prpl@mail.cc.nih.gov    
Contact: TTY     1-866-411-1010    

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike     Recruiting
      Bethesda, Maryland, United States, 20892

Sponsors and Collaborators
  More Information


NIH Clinical Center Detailed Web Page  This link exits the ClinicalTrials.gov site
 

Publications:

Study ID Numbers:   020263, 02-M-0263
First Received:   August 16, 2002
Last Updated:   July 18, 2008
ClinicalTrials.gov Identifier:   NCT00044096
Health Authority:   United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
SSRI  
Anxiety  
Stress  
Citalopram  
Benadryl  
Diphenhydramine  
Startle
Fear-Potentiated Startle
Fear
Normal Volunteers
Healthy Volunteers
HV

Study placed in the following topic categories:
Promethazine
Stress
Healthy
Dexetimide
Citalopram
Diphenhydramine

ClinicalTrials.gov processed this record on November 19, 2008




Links to all studies - primarily for crawlers